Tracers / [211At]At-NaAtO3
[211At]At-NaAtO3
Also written as [At-211]NaAtO3
- Radionuclide
- At-211 t½ 431 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Astatate salt (inorganic astatine species, [211At]astatate)
- Target / mechanism
- —
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | HPLC | — | — | [211At]NaAt | 36142567 2022 Int J Mol Sci To a 200 μL solution of 0.01 M NaIO4 in 0.1 N H2SO4 (200 μL) was added 100 μL solution containing 68 MBq (1.8 mCi) of [211At]NaAt. |
Need this precursor?We can point you to suppliers for [211At]At-NaAtO3, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 36142567. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 36142567: '[211At]NaAt'.